PharmaShots | Incisive News in 3 Shots

Subscribe Now

Bimekizumab

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

August 24, 2021

UCB Reports the FDA's and EMA's Acceptance of BLA and MAA for Bimekizumab to Treat Moderate to Severe Plaque Psoriasis

UCB Reports the FDA's and EMA's Acceptance of BLA and MAA for Bimekizumab to Treat Moderate to Severe Plaque Psoriasis

September 23, 2020

UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

October 24, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us